This is an open-label, multicenter Phase 1b/2 study to determine the maximum tolerated dose
(MTD) and/or recommended Phase 2 dose (RP2D) of ARRY-382 in combination with pembrolizumab in
adult patients with selected advanced solid tumors (Part A/Phase 1b); and to estimate the
efficacy of the combination in three separate cohorts: 1) patients with advanced solid tumors
that have progressed on prior PD-1/PD-L1inhibitors, 2) patients with platinum-resistant
ovarian cancer and 3) patients with pancreatic ductal adenocarcinoma (Phase 2).